Näytetään tulokset 1 - 10 / 22
tulosta / sivu
Mitä julkaisutietoja palvelu sisältää?
Julkaisun nimi
Tekijät
Julkaisukanava
Vuosi
 Julkaisujen tiedon ikoni

Itraconazole Increases Ibrutinib Exposure 10-Fold and Reduces Interindividual Variation-A Potentially Beneficial Drug-Drug Interaction

Vertaisarvioitu
Avoin saatavuus
DOI
10.1111/cts.12716
Tapaninen, Tuija; Olkkola, Aleksi M.; Tornio, Aleksi; Neuvonen, Mikko; Elonen, Erkki; Neuvonen, Pert...
Cts: clinical and translational science2020 Julkaisujen tiedon ikoni

Posaconazole-ibrutinib interaction cannot be avoided by staggered dosing: How to optimize ibrutinib dose during posaconazole treatment

Vertaisarvioitu
Avoin saatavuus
DOI
10.1111/bcp.15932
Olkkola, Aleksi M.; Tapaninen, Tuija; Tornio, Aleksi; Hauta-aho, Milka; Lapatto-Reiniluoto, Outi; Ne...
British journal of clinical pharmacology2023 Julkaisujen tiedon ikoni

Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

DOI
10.1182/blood.2020008608
Niemann CU, Levin MD, Dubois J, Kersting S, Enggaard L, Veldhuis GJ, Mous R, Mellink CHM, Dobber JA,...
Blood2020 Julkaisujen tiedon ikoni

Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

Vertaisarvioitu
Niemann U C; Levin M-U; Dubois J; Kersting S; et al.; Ranti J
Blood2020 Julkaisujen tiedon ikoni

Posaconazole-ibrutinib interaction cannot be avoided by staggered dosing: Hoe to optimize ibrtinib dose during posaconazole treatment

Vertaisarvioitu
Olkkola AM; Tapaninen T; Tornio A; Hauta-aho M; Lapatto-Reiniluoto O; Neuvonen M; Kiiski JI; Neuvone...
British Journal of Pharmacology2023 Julkaisujen tiedon ikoni

Ibrutinib, lenalidomide, and rituximab in relapsed mantle cell lymphoma:Long-term follow-up of the Nordic Lymphoma Group MCL6 Philemon trial

Vertaisarvioitu
Avoin saatavuus
DOI
10.1002/hem3.70101
Forsgren, Elin; Jorgensen, Rasmus R. K.; Bentzen, Hans; Riise, Jon; Haaber, Jacob; Pasanen, Annika; ...
HemaSphere2025 Julkaisujen tiedon ikoni

Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial

Vertaisarvioitu
Avoin saatavuus
DOI
10.1016/S2352-3026(18)30019-X
Jerkeman, Mats; Eskelund, Christian Winther; Hutchings, Martin; Räty, Riikka; Wader, Karin Fahl; Lau...
The Lancet Haematology2018 Julkaisujen tiedon ikoni

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma

Vertaisarvioitu
Avoin saatavuus
DOI
10.1200/JCO.18.02403
PHOENIX Investigators; Younes, Anas; Sehn, Laurie H.; Johnson, Peter; Zinzani, Pier Luigi; Hong, Xia...
Journal of clinical oncology2019 Julkaisujen tiedon ikoni

Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial

Vertaisarvioitu
DOI
10.1016/S1470-2045(22)00220-0
Kater Arnon P., Levin Mark-David, Dubois Julie, Kersting Sabina, Enggaard Lisbeth, Veldhuis Gerrit J...
The Lancet Oncology2022 Julkaisujen tiedon ikoni

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia

Vertaisarvioitu
Avoin saatavuus
DOI
10.1056/NEJMoa2213093
GCLLSG CLL Study Grp; HOVON CLL Study Grp; Nordic CLL Study Grp; Israeli CLL Assoc; Canc Trials Irel...
The new england journal of medicine2023

Itraconazole Increases Ibrutinib Exposure 10-Fold and Reduces Interindividual Variation-A Potentially Beneficial Drug-Drug Interaction

Vertaisarvioitu
Avoin saatavuus
DOI
10.1111/cts.12716
2020

Posaconazole-ibrutinib interaction cannot be avoided by staggered dosing: How to optimize ibrutinib dose during posaconazole treatment

Vertaisarvioitu
Avoin saatavuus
DOI
10.1111/bcp.15932
2023

Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

DOI
10.1182/blood.2020008608
2020

Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

Vertaisarvioitu
2020

Posaconazole-ibrutinib interaction cannot be avoided by staggered dosing: Hoe to optimize ibrtinib dose during posaconazole treatment

Vertaisarvioitu
2023

Ibrutinib, lenalidomide, and rituximab in relapsed mantle cell lymphoma:Long-term follow-up of the Nordic Lymphoma Group MCL6 Philemon trial

Vertaisarvioitu
Avoin saatavuus
DOI
10.1002/hem3.70101
2025

Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial

Vertaisarvioitu
Avoin saatavuus
DOI
10.1016/S2352-3026(18)30019-X
2018

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma

Vertaisarvioitu
Avoin saatavuus
DOI
10.1200/JCO.18.02403
2019

Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial

Vertaisarvioitu
DOI
10.1016/S1470-2045(22)00220-0
2022

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia

Vertaisarvioitu
Avoin saatavuus
DOI
10.1056/NEJMoa2213093
2023